Next Article in Journal
19β,28-Epoxy-18α-olean-3β-ol-2-furoate from Allobetulin (19β,28-Epoxy-18α-olean-3β-ol)
Previous Article in Journal
4,4′-(Butane-1,4-diyl)bis(4-methyl-1,2-dioxolane-3,5-dione)
 
 
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Synthesis and Crystal Structures of Halogen-Substituted 2-Aryl-N-phenylbenzimidazoles

1
N.S. Kurnakov Institute of General and Inorganic Chemistry of the Russian Academy of Sciences, Leninskii pr. 31, 119991 Moscow, Russia
2
Department of Chemistry, Lomonosov Moscow State University, Lenin’s Hills 1, 119991 Moscow, Russia
3
Laboratory for Magnetic Tomography and Spectroscopy, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, Lenin’s Hills 1, 119991 Moscow, Russia
*
Authors to whom correspondence should be addressed.
Molbank 2022, 2022(4), M1498; https://doi.org/10.3390/M1498
Received: 30 September 2022 / Revised: 14 November 2022 / Accepted: 16 November 2022 / Published: 18 November 2022

Abstract

:
Four 2-arylbenzimidazoles (aryl = 4-Br-phenyl (1), 3-Br-phenyl (2), 4-I-phenyl (3), 3-I-phenyl (4)) were synthesized and characterized by 1H, 13C{1H} NMR, UV–Vis spectroscopy and single-crystal X-ray diffraction. Both pairs of benzimidazoles bearing the halogen atom at the same position form isostructural crystals, in which para-substituted compounds 1 and 3 are assembled by weak C–H···π and π···π interactions while their meta-isomers 2 and 4 are linked via intermolecular halogen···nitrogen and C–H···π contacts.

1. Introduction

Benzimidazoles are widespread in medicinal chemistry as building blocks for the synthesis of bioactive compounds [1,2,3,4]. In particular, 2-arylbenzimidazoles have found application as various antiviral, antihistamine, and antitumor agents, etc. [5,6,7,8]. Growing interest to benzimidazoles has motivated researchers to develop numerous high-yield synthetic routes to these compounds [9,10,11,12]. Thus, benzimidazoles with virtually unlimited sets of functional substituents and/or degrees of conjugation can now be prepared, making them very attractive for the construction of metal complexes for application in medicinal chemistry, optoelectronics and photovoltaics [13,14,15,16,17]. Recently, benzimidazole-based cyclometalated iridium(III) complexes were successfully prepared and used as emitters in organic light-emitting diodes [18,19] as well as dyes in solar cells [20,21,22]. In this work, we synthesized four 2-arylbenzimidazoles (Figure 1) bearing bromo- or iodo-substituents in para/meta positions of the phenyl ring and characterized them by 1H, 13C {1H} NMR, UV–Vis spectroscopy and single-crystal X-ray diffraction. The prepared compounds are interesting as versatile building blocks for the construction of metal complexes and, due to the presence of halogen atoms, may also be excellent starting compounds for the synthesis of various sophisticated organic substances through cross-coupling reactions [23,24,25].

2. Results and Discussion

The target compounds were prepared in high yield via condensation of N-Phenyl-o-phenylenediamine with the corresponding halogen-substituted benzaldehyde in the presence of sodium metabisulfite (Scheme 1) [26,27].
The 1H NMR spectra of benzimidazoles 14 are similar and contain partially resolved as well as heavily overlapped multiplets in the range of 7.0–8.0 ppm (Figures S1, S3, S5 and S10). The signals were assigned by using 2D correlation NMR spectroscopy (for compounds 3 and 4, see Figures S7–S9 and S12–S14). In the 13C{1H} NMR spectra, the number of signals corresponds to the number of magnetically nonequivalent carbon atoms, which supports the composition and structure of the obtained compounds (Figures S2, S4, S6 and S11). The structures of 14 were unambiguously confirmed by single-crystal X-ray diffraction (Table S1).
The prepared 2-arylbenzimidazoles are isostructural in pairs (para-bromine with para-iodine and meta-bromine with meta-iodine) and produce monoclinic crystals which do not contain solvent molecules. Compounds 1 and 3 are also isostructural to 2-(4-chlorophenyl)-1-phenyl-benzimidazole [28] and 2-(4-bromophenyl)-1-phenyl-benzimidazole whose crystal structure was reported as a CSD private communication (ref code CINTIE). Unit cell volume is slightly increased (by a factor of 1.02) upon the replacement of bromo- by iodo-substituent while the position of the substituent has a smaller effect on the cell volume (less than 1% increase, see Table S1). The molecular structures of halogenated benzimidazoles 14 are shown in Figure 2.
The organic molecules consist of three non-coplanar aromatic fragments: the benzimidazole and N-phenyl ring, unchanged in the series, and the variable 2-phenyl ring containing halogen substituent in positions 3 or 4. The C–Br and C–I bond lengths lie within the ranges 1.898(3)–1.8986(13) and 2.097(3)–2.1038(15) Å, which are consistent with the average values from the Cambridge Structural Database (Version 5.43, March 2022, Cambridge, UK). The dihedral angles between the benzimidazole unit and the N-phenyl ring are in the range from 66.28(11) to 67.48(11)° for 1 and 3 and varies within 54.84(6)–56.71(6)° for 2 and 4. At the same time, the interplanar angles between the 2-aryl fragment and the same benzimidazole system for the para-substituted compounds are significantly smaller (24.09(10)–24.48(10)°) than the same angles in the meta-substituted compounds (39.23(6)–41.81(5)°). The values of these angles for each pair of isostructural compounds correlate with each other, and the greater the tilting of the pendant N-phenyl substituent, the smaller the slope of the 2-aryl ring in relation to the benzimidazole system. The latter is very likely governed by intermolecular interactions, in which the halogen atom of the aryl ring seems to play a more pronounced role than the N-phenyl ring.
Indeed, the Hal···N intermolecular contacts determine the crystal packing of 2 and 4 (d(Br···N) = 3.0945(11), d(I···N) = 3.0810(13) Å) [29] assembling molecules in chains along the b direction. These chains are linked by several C–H···π contacts, forming a 3D packing of the crystal (Figures S15 and S16). In the crystals of compounds 1 and 3, weak π···π interactions between the aromatic rings C1–C6 (substituted aryl) and C14–C19 (benzimidazole) arrange molecules in centrosymmetric dimers with d(π···π)centroid–centroid = 3.9974(17) Å and a shift between the centroids of 2.476(4) Å (Figure S17). These dimers are additionally stabilized by C–H···π contacts. The halogen atom is involved only in weak Hal···π interactions with d(Hal···π) = 4.1229(12)–4.1992(6) Å while several C–H···π contacts complete the 3D packing of the crystals.

3. Materials and Methods

3.1. General Comment

All commercially available reagents, except N-phenyl-o-phenylenediamine, were at least reagent grade and used without further purification. Solvents were distilled and dried according to standard procedures. Purification of N-phenyl-o-phenylenediamine was carried out according to the following method. A weighed portion of the diamine was dissolved in a minimum amount of solvent (mixture of hexane and ethyl acetate in a 3:1 volume ratio) and then passed through a chromatographic column (SiO2, hexane/ethyl acetate 3:1 vol.). A green solution was obtained, after evaporation of which dark green crystals precipitated. They were dissolved in ethanol and used for the synthesis of 2-arylbenzimidazoles.
The 1H, 13C and 2D NMR spectra were acquired at 25 °C on a Bruker Avance 400 and 600 instruments (Billerica, MA, USA) and chemical shifts were reported in ppm referenced to residual solvent signals (atom numbering for spectra assignment is presented in Figure 3). The electronic absorption spectra of 14 in CH2Cl2 (C ≈ 2 × 10−5 M) were measured on an OKB Spectr SF-2000 spectrophotometer (Saint Petersburg, Russia) (see Figure S18). Melting points of 14 were measured at a Linkam DSC600 optical system (Salfords, UK) equipped with an Olympus BX43 polarized light microscope (Tokyo, Japan) at a heating rate of 5 deg·min−1.

3.2. Synthesis

1-Phenyl-2-(4-bromophenyl)benzimidazole (1). A solution of purified N-Phenyl-o-phenylenediamine (1.0488 g, 5.7 mmol) and p-bromobenzaldehyde (1.0550 g, 5.7 mmol) in ethanol were mixed with Na2S2O5 (1.0830 g, 5.7 mmol) and refluxed under argon for 3 h. After separation of a precipitate by decantation, the filtrate was evaporated to dryness and dried in vacuo (yield 89%).
Figure 3. H and C Atom numbering in 14.
Figure 3. H and C Atom numbering in 14.
Molbank 2022 m1498 g003
1H NMR (400 MHz, CDCl3, δ): 7.90–7.88 (m, 1H, m), 7.55–7.49 (m, 3H, f–h), 7.44 (s, 4H, a–d), 7.37–7.23 (m, 5H, e, i–l).
13C{1H} NMR (101 MHz, CDCl3, δ): 150.81 (7), 142.49 (19), 136.83 (14), 136.31 (8), 131.17 (2, 4), 130.45 (1, 5), 129.63 (10. 12), 128.47 (6), 128.39 (11), 126.95 (9, 13), 123.66 (3), 123.21 (16), 122.7 (17), 119.49 (18), 110.11 (15).
Mp: 166–167 °C.
UV–Vis (CH2Cl2): λmax 297 nm (ε = 24,000 M−1 cm−1).
1-Phenyl-2-(3-bromophenyl)benzimidazole (2) was prepared as 1, yield 88%.
1H NMR (400 MHz, CDCl3, δ): 7.95–7.81 (m, 2H, d, m), 7.55–7.46 (m, 4H, c, f–h), 7.38–7.21 (m, 6H, a, e, i–l), 7.12 (t, J = 7.9 Hz, 1H, b).
13C{1H} NMR (101 MHz, CDCl3, δ): 150.23 (7), 142.42 (19), 136.81 (14), 136.16 (8), 132.01 (3, 5), 131.49 (6), 129.63 (10, 12), 129.29 (2), 128.48 (11), 127.34 (1), 126.95 (9, 13), 123.35 (16), 122.84 (17), 122.07 (4), 119.59 (18), 110.17 (15).
Mp: 122–123 °C.
UV–Vis (CH2Cl2): λmax 298 nm (ε = 22,000 M−1 cm−1).
1-Phenyl-2-(4-iodophenyl)benzimidazole (3) was prepared as 1, yield 85%.
1H NMR (400 MHz, CDCl3, δ): 7.83 (d, J = 8.0 Hz, 1H, m), 7.62–7.57 (m, 2H, b, c), 7.55–7.48 (m, 3H, f–h),7.32–7.28 (m, 1H, l), 7.28–7.25 (m, 2H, e, i), 7.25–7.23 (m, 2H, a, d), 7.23–7.20 (m, 1H, k), 7.20–7.17 (m, 1H, j).
13C{1H} NMR (101 MHz, CDCl3, δ): 150.91 (7), 142.49 (19), 137.10 (2, 4), 136.85 (14), 136.32 (8), 130.50 (1, 5), 129.63 (10, 12), 129.03 (6), 128.40 (11), 126.95 (9, 13), 123.22 (16), 122.78 (17), 119.50 (18), 110.11 (15), 95.72 (3).
Mp: 164–165 °C.
UV–Vis (CH2Cl2): λmax 304 nm (ε = 19,000 M−1 cm−1).
1-Phenyl-2-(3-iodophenyl)benzimidazole (4) was prepared as 1, yield 81%.
1H NMR (600 MHz, CDCl3, δ): 8.06–8.01 (m, 1H, d), 7.87–7.82 (m, 1H, m), 7.65–7.61 (m, 1H, c), 7.51–7.43 (m, 3H, f–h), 7.36–7.32 (m, 1H, a), 7.32–7.28 (m, 1H, l), 7.28–7.24 (m, 2H, e, i), 7.24–7.22 (m, 1H, k), 7.22–7.18 (m, 1H, j), 6.94 (t, J = 7.8 Hz, 1H, b).
13C{1H} NMR (101 MHz, CDCl3, δ): 150.07 (7), 142.43 (19), 137.92 (3), 137.87 (5), 136.79 (14), 136.18 (8), 131.47 (6), 129.61 (10, 12), 129.33 (2), 128.46 (11), 127.90 (1), 126.96 (9, 13), 123.31 (16), 122.82 (17), 119.58 (18), 110.15 (15), 93.65 (4).
Mp: 158–160 °C.
UV–Vis (CH2Cl2): λmax 297 nm (ε = 18,000 M−1 cm−1).

3.3. Crystallography Details

Single crystals of 14 were grown by slow evaporation of the solution of the benzimidazoles in dichloromethane. Crystallographic data were collected on a Bruker SMART APEX II and D8 Venture diffractometers using graphite monochromatized Mo–Kα radiation (λ = 0.71073 Å) using ω-scan mode. Absorption correction based on the measurements of equivalent reflections was applied [30]. The structures were solved by direct methods and refined by full matrix least-squares on F2 with anisotropic thermal parameters for all non-hydrogen atoms [31,32]. Hydrogen atoms were placed in calculated positions and refined using a riding model. The crystallographic details are presented in Table S1 and the crystal packings are plotted in Figures S15–S17. CCDC 2210233–2210236 contains the supplementary crystallographic data for 14. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
Crystal Data for 1: C19H13N2Br (M = 349.22 g/mol): monoclinic, space group P21/n (no. 14), a = 8.3061(15) Å, b = 9.4657(14) Å, c = 19.288(4) Å, β = 90.276(7)°, V = 1516.5(5) Å3, Z = 4, T = 150(2) K, μ(MoKα) = 2.708 mm−1, Dcalc = 1.530 g/cm3, 15,241 reflections measured (4.22° ≤ 2Θ ≤ 50.10°), 2681 unique (Rint = 0.0548, Rsigma = 0.0377) which were used in all calculations. The final R1 was 0.0327 (I > 2σ(I)) and wR2 was 0.0750 (all data), max/min ΔF 0.24/−0.44 e/Å3.
Crystal Data for 2: C19H13N2Br (M = 349.22 g/mol): monoclinic, space group P21/c (no. 14), a = 8.6166(7) Å, b = 10.1262(8) Å, c = 17.6938(14) Å, β = 98.201(3)°, V = 1528.1(2) Å3, Z = 4, T = 150(2) K, μ(MoKα) = 2.687 mm−1, Dcalc = 1.518 g/cm3, 71,674 reflections measured (4.65° ≤ 2Θ ≤ 61.81°), 4740 unique (Rint = 0.0350, Rsigma = 0.0141) which were used in all calculations. The final R1 was 0.0271 (I > 2σ(I)) and wR2 was 0.0724 (all data), max/min ΔF 0.56/−0.57 e/Å3.
Crystal Data for 3: C19H13N2I (M = 396.21 g/mol): monoclinic, space group P21/n (no. 14), a = 8.1539(2) Å, b = 9.6185(2) Å, c = 19.6442(5) Å, β = 91.9830(10)°, V = 1539.74(6) Å3, Z = 4, T = 150(2) K, μ(MoKα) = 2.077 mm−1, Dcalc = 1.709 g/cm3, 19,425 reflections measured (4.15° ≤ 2Θ ≤ 63.07°), 5125 unique (Rint = 0.0255, Rsigma = 0.0246) which were used in all calculations. The final R1 was 0.0235 (I > 2σ(I)) and wR2 was 0.0534 (all data), max/min ΔF 0.41/−0.68 e/Å3.
Crystal Data for 4: C19H13N2I (M = 396.21 g/mol): monoclinic, space group P21/c (no. 14), a = 8.4708(5) Å, b = 10.0913(6) Å, c = 18.2452(12) Å, β = 98.622(2)°, V = 1542.00(16) Å3, Z = 4, T = 100(2) K, μ(MoKα) = 2.074 mm−1, Dcalc = 1.707 g/cm3, 17,807 reflections measured (4.52° ≤ 2Θ ≤ 62.99°), 5060 unique (Rint = 0.0264, Rsigma = 0.0271) which were used in all calculations. The final R1 was 0.0210 (I > 2σ(I)) and wR2 was 0.0461 (all data), max/min ΔF 0.52/−0.46 e/Å3.

Supplementary Materials

The following are available online. Part 1. NMR spectroscopy data: Figures S1–S14; Part 2. X-ray crystallography: Table S1, Figures S15–S17; Part 3. Optical data: Figure S18.

Author Contributions

Conceptualization, S.I.B. and A.Y.Z.; methodology, P.K.; validation, A.G.K.; formal analysis, A.G.K. and P.K.; investigation, S.I.B. and A.Y.Z.; resources, A.V.C. and S.I.B.; data curation, M.A.K., S.S.M. and S.I.B.; writing—original draft preparation, M.A.K. and S.I.B.; writing—review and editing, A.V.C.; visualization, M.A.K. and A.G.K.; supervision, S.I.B. and A.V.C.; project administration, S.I.B. and A.V.C.; funding acquisition, S.I.B. All authors have read and agreed to the published version of the manuscript.

Funding

The work was carried out within the State Assignment on Fundamental Research to the N.S. Kurnakov Institute of General and Inorganic Chemistry of the Russian Academy of Sciences (№ 1021071612841-6-1.4.7).

Data Availability Statement

Data are contained within the article and SI.

Acknowledgments

X-ray diffraction studies were performed at the Centre of Shared Equipment of the N.S. Kurnakov Institute of General and Inorganic Chemistry of the Russian Academy of Sciences.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Vasava, M.S.; Bhoi, M.N.; Rathwa, S.K.; Jethava, D.J.; Acharya, P.T.; Patel, D.B.; Patel, H.D. Benzimidazole: A milestone in the field of medicinal chemistry. Mini-Rev. Med. Chem. 2020, 20, 532–565. [Google Scholar] [CrossRef] [PubMed]
  2. Hernández-López, H.; Tejada-Rodríguez, C.J.; Leyva-Ramos, S. A Panoramic Review of Benzimidazole Derivatives and Their Potential Biological Activity. Mini-Rev. Med. Chem. 2022, 22, 1268–1280. [Google Scholar] [CrossRef]
  3. Pathare, B.; Bansode, T. Review—Biological Active Benzimidazole Derivatives. Results Chem. 2021, 3, 100200. [Google Scholar] [CrossRef]
  4. Leila, D.; Gokhan, Z.; Mir, B.B. Cholinesterases inhibitory activity of 1H-benzimidazole derivatives. Biointerface Res. Appl. Chem. 2020, 11, 10739–10745. [Google Scholar] [CrossRef]
  5. Panda, S.; Malik, R.; Jain, S.C. Synthetic approaches to 2-arylbenzimidazoles: A review. Curr. Org. Chem. 2012, 16, 1905–1919. [Google Scholar] [CrossRef]
  6. Basha, N.J. Therapeutic efficacy of benzimidazole and its analogs: An update. Polycycl. Aromat. Compd. 2022, 1–21. [Google Scholar] [CrossRef]
  7. G, A.C.; Gondru, R.; Li, Y.; Banothu, J. Coumarin–benzimidazole hybrids: A review of developments in medicinal chemistry. Eur. J. Med. Chem. 2022, 227, 113921. [Google Scholar] [CrossRef]
  8. Shatokhin, S.S.; Tuskaev, V.A.; Gagieva, S.C.; Markova, A.A.; Pozdnyakov, D.I.; Melnikova, E.K.; Bulychev, B.M.; Oganesyan, E.T. Synthesis, Cytotoxic and antioxidant activities of new n-substituted 3-(benzimidazol-2-Yl)-chromones containing 2,6-di-Tert-butylphenol fragment. J. Mol. Struct. 2022, 1249, 131683. [Google Scholar] [CrossRef]
  9. Mamedov, V.A.; Zhukova, N.A. Recent developments towards synthesis of (Het) arylbenzimidazoles. Synthesis 2021, 53, 1849–1878. [Google Scholar] [CrossRef]
  10. Sigh, K.S.; Joy, F.; Devi, P. Ruthenium(II)-catalyzed synthesis of 2-arylbenzimidazole and 2-arylbenzothiazole in water. Transit. Met. Chem. 2021, 46, 181–190. [Google Scholar] [CrossRef]
  11. Tzani, M.A.; Gabriel, C.; Lykakis, I.N. Selective synthesis of benzimidazoles from o-phenylenediamine and aldehydes promoted by supported gold nanoparticles. Nanomaterials 2020, 10, 2405. [Google Scholar] [CrossRef] [PubMed]
  12. Bhavsar, Z.A.; Acharya, P.T.; Jethava, D.J.; Patel, D.B.; Vasava, M.S.; Rajani, D.P.; Pithawala, E.; Patel, H.D. Microwave assisted synthesis, biological activities, and in silico investigation of some benzimidazole derivatives. J. Heterocycl. Chem. 2020, 57, 4215–4238. [Google Scholar] [CrossRef]
  13. Ridley, H.F.; Spickett, R.G.W.; Timmis, G.M. A new synthesis of benzimidazoles and aza-analogs. J. Heterocycl. Chem. 1965, 2, 453–456. [Google Scholar] [CrossRef]
  14. Lavrova, M.A.; Mishurinskiy, S.A.; Smirnov, D.E.; Kalle, P.; Krivogina, E.V.; Kozyukhin, S.A.; Emets, V.V.; Mariasina, S.S.; Dolzhenko, V.D.; Bezzubov, S.I. Cyclometalated Ru (Ii) Complexes with tunable redox and optical properties for dye-sensitized solar cells. Dalt. Trans. 2020, 49, 16935–16945. [Google Scholar] [CrossRef] [PubMed]
  15. Aroso, R.T.; Guedes, R.C.; Pereira, M.M. Synthesis of computationally designed 2,5(6) -benzimidazole derivatives via pd-catalyzed reactions for potential, e. coli dna gyrase b inhibition. Molecules 2021, 26, 1326. [Google Scholar] [CrossRef]
  16. Yellol, J.; Pérez, S.A.; Buceta, A.; Yellol, G.; Donaire, A.; Szumlas, P.; Bednarski, P.J.; Makhloufi, G.; Janiak, C.; Espinosa, A.; et al. Novel c,n-cyclometalated benzimidazole ruthenium(ii) and iridium(iii) complexes as antitumor and antiangiogenic agents: A structure–activity relationship study. J. Med. Chem. 2015, 58, 7310–7327. [Google Scholar] [CrossRef]
  17. Munnik, B.L.; Kaschula, C.H.; Watson, D.J.; Wiesner, L.; Loots, L.; Chellan, P. Synthesis and study of organometallic pgm complexes containing 2-(2-pyridyl) benzimidazole as antiplasmodial agents. Inorg. Chim. Acta 2022, 540, 121039. [Google Scholar] [CrossRef]
  18. Laha, P.; Husain, A.; Patra, S. Tuning the emission maxima of iridium systems using benzimidazole-based cyclometallating Framework. J. Mol. Liq. 2022, 349, 118446. [Google Scholar] [CrossRef]
  19. Buil, M.L.; Esteruelas, M.A.; López, A.M. Recent advances in synthesis of molecular heteroleptic osmium and iridium phosphorescent emitters. Eur. J. Inorg. Chem. 2021, 2021, 4731–4761. [Google Scholar] [CrossRef]
  20. Bezzubov, S.I.; Kiselev, Y.M.; Churakov, A.V.; Kozyukhin, S.A.; Sadovnikov, A.A.; Grinberg, V.A.; Emets, V.V.; Doljenko, V.D. Iridium (III) 2-phenylbenzimidazole complexes: Synthesis, structure, optical properties, and applications in dye-sensitized solar cells. Eur. J. Inorg. Chem. 2016, 2016, 347–354. [Google Scholar] [CrossRef]
  21. Wang, L.; Cui, P.; Lystrom, L.; Lu, J.; Kilina, S.; Sun, W. Heteroleptic cationic iridium (iii) complexes bearing phenanthroline derivatives with extended π-conjugation as potential broadband reverse saturable absorbers. New J. Chem. 2019, 44, 456–465. [Google Scholar] [CrossRef]
  22. Bezzubov, S.I.; Zharinova, I.S.; Khusyainova, A.A.; Kiselev, Y.M.; Taydakov, I.V.; Varaksina, E.A.; Metlin, M.T.; Tobohova, A.S.; Korshunov, V.M.; Kozyukhin, S.A.; et al. Aromatic beta-diketone as a novel anchoring ligand in iridium (iii) complexes for dye-sensitized solar cells. Eur. J. Inorg. Chem. 2020, 2020, 3277–3286. [Google Scholar] [CrossRef]
  23. Largeron, M.; Nguyen, K. Recent advances in the synthesis of benzimidazole derivatives from the oxidative coupling of primary amines. Synthesis 2018, 50, 241–253. [Google Scholar] [CrossRef]
  24. Brunen, S.; Grell, Y.; Steinlandt, P.S.; Harms, K.; Meggers, E. Bis-cyclometalated indazole and benzimidazole chiral-at-iridium complexes: Synthesis and asymmetric catalysis. Molecules 2021, 26, 1822. [Google Scholar] [CrossRef] [PubMed]
  25. Martin, A.D.; Siamaki, A.R.; Belecki, K.; Gupton, B.F. A convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction between two functionalized benzimidazoles. J. Org. Chem. 2015, 80, 1915–1919. [Google Scholar] [CrossRef]
  26. Bezzubov, S.I.; Doljenko, V.D.; Troyanov, S.I.; Kiselev, Y.M. Tuning the photophysical and electrochemical properties of iridium(iii)2-aryl-1-phenylbenzimidazole complexes. Inorg. Chim. Acta 2014, 415, 22–30. [Google Scholar] [CrossRef]
  27. Smirnov, D.E.; Tatarin, S.V.; Bezzubov, S.I. Synthesis and crystal structures of n -h, n -phenyl and n -benzyl-2-(4-hexyloxyphenyl)benzimidazoles. Acta Crystallogr. Sect. E Crystallogr. Commun. 2021, 77, 618–622. [Google Scholar] [CrossRef]
  28. Kassim, K.; Hashim, N.Z.N.; Fadzil, A.H.; Yusof, M.S.M. 2-(4-Chlorophenyl)-1-phenyl-1 H -benzimidazole. Acta Crystallogr. Sect. E Struct. Rep. Online 2012, 68, o799. [Google Scholar] [CrossRef]
  29. Su, Y.-J.; Huang, H.-L.; Li, C.-L.; Chien, C.-H.; Tao, Y.-T.; Chou, P.-T.; Datta, S.; Liu, R.-S. Highly efficient red electrophosphorescent devices based on iridium isoquinoline complexes: Remarkable external quantum efficiency over a wide range of current. Adv. Mater. 2003, 15, 884–888. [Google Scholar] [CrossRef]
  30. Sheldrick, G.M. A short history of shelx. Acta Crystallogr. Sect. A Found. Cryst. 2008, 64, 112–122. [Google Scholar] [CrossRef]
  31. Sheldrick, G.M. SHELXT—Integrated space-group and crystal-structure determination. Acta Crystallogr. Sect. A Found. Cryst. 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
  32. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A complete structure solution, refinement and analysis program. J. Appl. Cryst. 2009, 42, 339–341. [Google Scholar] [CrossRef]
Figure 1. Chemical structures of studied halogen-substituted 2-aryl-N-phenylbenzimidazoles.
Figure 1. Chemical structures of studied halogen-substituted 2-aryl-N-phenylbenzimidazoles.
Molbank 2022 m1498 g001
Scheme 1. Synthesis of halogen-substituted (in para- and meta-positions) 2-arylbenzimidazoles.
Scheme 1. Synthesis of halogen-substituted (in para- and meta-positions) 2-arylbenzimidazoles.
Molbank 2022 m1498 sch001
Figure 2. Molecular structures of halogen-substituted 2-arylbenzimidazoles (compounds 14). Displacement ellipsoids are shown at 50% probability level.
Figure 2. Molecular structures of halogen-substituted 2-arylbenzimidazoles (compounds 14). Displacement ellipsoids are shown at 50% probability level.
Molbank 2022 m1498 g002
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Koptyaeva, A.G.; Zakharov, A.Y.; Kiseleva, M.A.; Mariasina, S.S.; Kalle, P.; Churakov, A.V.; Bezzubov, S.I. Synthesis and Crystal Structures of Halogen-Substituted 2-Aryl-N-phenylbenzimidazoles. Molbank 2022, 2022, M1498. https://doi.org/10.3390/M1498

AMA Style

Koptyaeva AG, Zakharov AY, Kiseleva MA, Mariasina SS, Kalle P, Churakov AV, Bezzubov SI. Synthesis and Crystal Structures of Halogen-Substituted 2-Aryl-N-phenylbenzimidazoles. Molbank. 2022; 2022(4):M1498. https://doi.org/10.3390/M1498

Chicago/Turabian Style

Koptyaeva, Anastasia G., Alexander Y. Zakharov, Marina A. Kiseleva, Sofia S. Mariasina, Paulina Kalle, Andrei V. Churakov, and Stanislav I. Bezzubov. 2022. "Synthesis and Crystal Structures of Halogen-Substituted 2-Aryl-N-phenylbenzimidazoles" Molbank 2022, no. 4: M1498. https://doi.org/10.3390/M1498

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop